ZENI.ST Zenicor Medical Systems AB
- Market cap
- SEK 23.6M
- P/E
- 30.0x
- P/B
- 0.36x
- ROE
- 1.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ZENI.ST undervalued?
Graham numberZENI.ST trades 30.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zenicor Medical Systems AB fundamental analysis
No fundamental analysis for Zenicor Medical Systems AB yet.
Zenicor Medical Systems AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zenicor Medical Systems AB
Zenicor Medical Systems AB (publ), a medical technology company, develops systems and care chains for the diagnosis of arrhythmia and stroke prevention. The company offers Zenicor One, a handheld ECG device for arrhythmia; Zenicor Flex, a device that provides ECG data and arrhythmia detection; and Zenicor View, a web-based system solution for all types of arrhythmia investigations. It also provides Zenicor Direct, a solution with interpretation services and services for devi…
Full company profileZenicor Medical Systems AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zenicor Medical Systems AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 17.9M | 19.7M | 21.5M | 24.2M | 25.2M | 27.9M | 30.2M |
| Gross Profit | - | 19.0M | 20.8M | 24.3M | 28.3M | 28.1M | 27.4M | 28.0M |
| Operating Income | - | 1.79M | 1.21M | -765K | -4.11M | 126K | 2.11M | 2.14M |
| EBITDA | - | - | - | 92.9K | -852K | 4.46M | 6.65M | 6.55M |
| Net Income | - | 1.43M | 629K | -1.75M | -5.59M | -2.08M | 214K | 539K |
| EPS | - | 0.22 | 0.10 | -0.27 | -0.62 | -0.23 | 0.01 | 0.02 |
| Balance Sheet | ||||||||
| Total Assets | - | 33.0M | 40.4M | 45.9M | 60.2M | 63.2M | 77.7M | 78.6M |
| Total Liabilities | - | 15.6M | 22.4M | 29.6M | 29.6M | 34.8M | 20.8M | 21.9M |
| Shareholders' Equity | - | 17.4M | 18.0M | 16.3M | 30.6M | 28.5M | 56.9M | 56.7M |
| Cash & Short-term Investments | - | 1.19M | 1.07M | 589K | 3.12M | 912K | 5.11M | 268K |
| Cash Flow | ||||||||
| Operating Cash Flow | - | 2.89M | 2.49M | 5.87M | -7.04M | -596K | -9.74M | -6.11M |
| Capital Expenditure | 0.00 | 5.33M | 6.34M | 12.5M | 8.22M | 6.96M | 5.30M | 3.65M |
| Free Cash Flow | - | -2.44M | -3.85M | -6.58M | -15.3M | -7.56M | -15.0M | -9.76M |
| Ratios | ||||||||
| ROE | - | 8.2% | 3.5% | -10.7% | -18.3% | -7.3% | 0.4% | 1.0% |
| ROA | - | 4.3% | 1.6% | -3.8% | -9.3% | -3.3% | 0.3% | 0.7% |
| Net Profit Margin | - | 7.9% | 3.2% | -8.1% | -23.1% | -8.3% | 0.8% | 1.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zenicor Medical Systems AB dividends
Zenicor Medical Systems AB has not paid dividends in the last 8 fiscal years.
Who owns Zenicor Medical Systems AB
- Insiders 50.24%
- Institutions 8.57%
- Public & others 41.19%
- Shares outstanding 26.2M
- Free float 13.2M
Zenicor Medical Systems AB company profile
- Company name
- Zenicor Medical Systems AB
- Ticker
- ZENI.ST
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Real Estate Management & Development
- Employees
- 20
- Fiscal year end
- December
- Address
- Saltmätargatan 8, Stockholm, Sweden, 113 59
- Phone
- 46 84 42 68 60
- Website
- zenicor.se
About Zenicor Medical Systems AB
Zenicor Medical Systems AB (publ), a medical technology company, develops systems and care chains for the diagnosis of arrhythmia and stroke prevention. The company offers Zenicor One, a handheld ECG device for arrhythmia; Zenicor Flex, a device that provides ECG data and arrhythmia detection; and Zenicor View, a web-based system solution for all types of arrhythmia investigations. It also provides Zenicor Direct, a solution with interpretation services and services for device logistics; and DeepRhythmAI, an AI technology of Zenicor Solution for modern arrhythmia diagnostics. The company was incorporated in 2003 and is headquartered in Stockholm, Sweden.
Zenicor Medical Systems AB management
2- Mr. Mats PaleriusCo-Founder, CEO & Director · born 1960
- Liz MuwangaSustainability Manager and Quality & Regulatory Affairs Specialist